India, Oct. 7 -- On Monday privately held Click Therapeutics Inc., a company developing software-based prescription medical treatments, said the U.S. FDA has granted 510 (k) clearance for Motivista.
Motivista (CT-155) is the first prescription digital therapeutic for the treatment of negative symptoms of schizophrenia. It is intended as an adjunct to clinician-managed outpatient care, including antipsychotic therapy, in adults aged 18 and older with clinically stable positive symptoms.
Schizophrenia is a chronic mental health disorder. Its negative symptoms include low motivation, reduced ability to experience pleasure and social withdrawal. These symptoms can persist even when positive symptoms, such as hallucinations and delusions, are ...